Finch Therapeutics and Takeda Pharmaceuticals entered into a partnership to develop a microbiome treatment for Crohn's disease, the companies announced Nov. 13.
What you should know:
1. The companies will use Finch's Human-First Discovery platform to develop the treatment. The platform develops treatments that contain microbiota from human donors as well as bacterial strains that contributed to favorable clinical outcomes in studies.
2. If Finch succeeds, Takeda will receive exclusive commercialization rights.
3. Neither company disclosed the financial terms of the deal.